Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKZF2 | Q9UKS7 | 5/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 15/20 | 0.52 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | IL1B | P01584 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30368918 | 1.00 | IKZF2 (0.52) | IKZF2CRBNIKZF1BRD4TNF | |
| SCHEMBL30369004 | 1.00 | IKZF2 (0.52) | IKZF2CRBNIKZF1BRD4TNF | |
| SCHEMBL30368899 | 1.00 | IKZF2 (0.52) | IKZF2CRBNIKZF1BRD4TNF | |
| SCHEMBL24080038 | 1.00 | IKZF2 (0.52) | IKZF2CRBNIKZF1BRD4TNF | |
| SCHEMBL30368896 | 1.00 | IKZF2 (0.52) | IKZF2CRBNIKZF1BRD4TNF | |
| SCHEMBL24080122 | 1.00 | IKZF2 (0.52) | IKZF2CRBNIKZF1BRD4TNF | |
| SCHEMBL30369208 | 1.00 | IKZF2 (0.52) | IKZF2CRBNIKZF1BRD4TNF | |
| SCHEMBL24079912 | 1.00 | IKZF2 (0.52) | IKZF2CRBNIKZF1BRD4TNF | |
| SCHEMBL21618188 | 1.00 | IKZF2 (0.52) | IKZF2CRBNIKZF1BRD4TNF | |
| SCHEMBL21621900 | 0.89 | CRBN (0.54) | IKZF2CRBNIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3820573-B1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2023-08-09 | — | — | EP | claimed |
| CN-112261970-A | 3- (5-hydroxy-1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives and their use in the treatment of IKAROS family Zinc finger 2(IKZF2) dependent diseases | 诺华股份有限公司 | 2021-01-22 | — | — | CN | claimed |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2021-12-07 | — | — | US | disclosed |
| CN-112261970-A | 3- (5-hydroxy-1-oxoisoindolin-2-yl) piperidine-2, 6-dione derivatives and their use in the treatment of IKAROS family Zinc finger 2(IKZF2) dependent diseases | 诺华股份有限公司 | 2021-01-22 | — | — | CN | disclosed |
| WO-2020012334-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES | NOVARTIS AG (CH) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192877-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | XDH, HTR1D, RXFP1 | IKZF2 3604/4885CRBN 3703/4885IKZF1 3031/4885 |
| US-20230067476-A1 | 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | XDH, HTR1D, RXFP1 | IKZF2 3604/4885CRBN 3703/4885IKZF1 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.